The health insurance company Cigna announced it has entered into a 10-year agreement with Catamaran, the nation’s fourth largest pharmacy benefits manager. With Cigna’s 8 million customers, the deal secures Catamaran’s place among the nation’s largest PBMs. We spoke to Adam Fein, founder and president of Pembroke Consulting, about the agreement, the importance PBMs like Catamaran play in the world of healthcare today, and what the growing power of these organizations mean to drugmakers. Read More
Drug Development
- NIH Expands Repurposing Efforts with New Grants
Institute awards $12.7 million total to nine academic groups. Read More
Obesity
- AMA Says Obesity Is a Disease
Vote at annual convention overrides committee recommendation Read More
Mergers and Acquisitions
- J&J Bets up to $1 Billion in Aragon Buy
Prostate cancer therapy sold while breast cancer therapy is spun into new company. Read More - Elan Shareholders Vote to Nix Royalty Pharma Takeover
Share buyback plan approved, but $1 billion Theravance royalty stream buy rejected. Read More
Patents
- SCOTUS Rules Pay-For-Delay Settlements Can Violate Antitrust Laws
Orders lower court to allow FTC to proceed with case. Read More - SCOTUS Rules Genes Can’t Be Patented
Decision upholds parts of Myriad’s Patents Read More
Deals
- Amgen Invests $25 Million to Expand Cytokinetics Agreement
Deal includes $10 million equity purchase. Read More
Trials and Tribulations
- Pfizer Reaches $2.15B Patent Dispute with Teva and Sun
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More
Comparative Effectiveness
- Cocktail of Generics as Good as Enbrel for Rheumatoid Arthritis
Study compared combination of disease-modifying anti-rheumatic drugs and methotrexate against high-priced biologic. Read More
Public Health
- G8 Science Ministers Spotlight Antibiotics Resistance
Group commits to greater cooperation and research to combat growing problem. Read More
- The Burrill Report (June 17, 2013): Cigna Deal Bulks up Catamaran's Muscle
Listen to the latest edition from The Journal of Life Sciences. Browse all podcasts
June 2013
Download a free copy of the June 2013 issue of The Burrill Report. This month's focus: Dealmaking
Click here to download
Diego Miralles, head of the Johnson & Johnson California Innovation Center, discusses how it will operate, some of the deals it’s already made, and whether large pharmaceuticals companies need to change to better recognize and drive innovative products to market.
Capital Scorecard
Filed IPOs
Completed IPOs
PDUFA Dates
Drug Approvals
Burrill Indices
Biggest Movers
Learn about the essential role remote monitoring will be play in controlling health care costs for Europe's aging population.
Read now
Amgen and Cytokinetics have expanded their strategic collaboration to provide the biotech giant rights in Japan to Cytokinetics’ experimental heart failure drug for a $15 million license fee./p>
.jpg)
.gif)
.png){kind=small} |
 |